©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. May 28, 2016; 22(20): 4794-4801
Published online May 28, 2016. doi: 10.3748/wjg.v22.i20.4794
Published online May 28, 2016. doi: 10.3748/wjg.v22.i20.4794
Inflammatory bowel disease and cancer: The role of inflammation, immunosuppression, and cancer treatment
Jordan E Axelrad, Simon Lichtiger, Department of Medicine, Division of Digestive and Liver Diseases, Columbia University Medical Center, New York, NY 10032, United States
Vijay Yajnik, Department of Medicine, Division of Gastroenterology, The Massachusetts General Hospital, Boston, MA 02445, United States
Author contributions: Axelrad JE, Lichtiger S and Yajnik V wrote the paper.
Conflict-of-interest statement: Authors declare no conflict of interests for this article.
Correspondence to: Vijay Yajnik, MD, PhD, Department of Medicine, Division of Gastroenterology, The Massachusetts General Hospital, Crohn’s and Colitis Center, 165 Cambridge Street 9th Floor, Boston, MA 02445, United States. vyajnik@mgh.harvard.edu
Telephone: +1-617-7246005 Fax: +1-617-7263080
Received: February 11, 2016
Peer-review started: February 11, 2016
First decision: March 21, 2016
Revised: March 25, 2016
Accepted: April 7, 2016
Article in press: April 7, 2016
Published online: May 28, 2016
Processing time: 98 Days and 11.9 Hours
Peer-review started: February 11, 2016
First decision: March 21, 2016
Revised: March 25, 2016
Accepted: April 7, 2016
Article in press: April 7, 2016
Published online: May 28, 2016
Processing time: 98 Days and 11.9 Hours
Core Tip
Core tip: Patients with inflammatory bowel disease (IBD) and cancer represent a challenging population. Gastroenterologists and oncologists caring for patients with IBD and cancer are increasingly confronted with questions regarding the management of IBD after a diagnosis of cancer, and conversely, the management of cancer in patients with IBD. This review seeks to explore the characteristics, risks, and pathogenesis of cancer in patients with IBD, and to evaluate the data on patients with IBD and cancer, including the interaction between IBD and cancer treatment.